menu
    • menu

    Company profile for ImmunityBio

    NEW Drugs in Dev: 45
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System. ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunityBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Culver City, CA 90232
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immunitybio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunitybio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Vietnam Medi-Pharm Expo

    Not Confirmed

    envelop Contact Supplier

    Vietnam Medi-Pharm Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunityBio Hits Record Q1 2026: $44M Revenue
    ImmunityBio Hits Record Q1 2026: $44M Revenue

    07 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-07/immunitybio-reports-record-q1-2026-results-net-product-revenue-increased-nearly-27x-year-over-year

    PHARMIWEB
    07 May 2026
    Share Share
    Robbins Geller: IBRX Investors Can Lead Class Action Suit
    Robbins Geller: IBRX Investors Can Lead Class Action Suit

    10 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-10/ibrx-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-immunitybio-inc-investors

    PHARMIWEB
    10 Apr 2026
    Share Share
    ImmunityBio Q1 2026: Revenue Up 2.7x to $44M, Cash $381M
    ImmunityBio Q1 2026: Revenue Up 2.7x to $44M, Cash $381M

    09 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-09/immunitybio-reports-net-product-revenue-increased-nearly-27-times-year-over-year-to-record-44-mill

    PHARMIWEB
    09 Apr 2026
    Share Share
    Immunitybio Responds To FDA Warning Letter With New Protocols
    Immunitybio Responds To FDA Warning Letter With New Protocols

    06 Apr 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/immunitybio-establish-new-protocols-clear-claims-related-its-cancer-drug

    FIERCE PHARMA
    06 Apr 2026
    Share Share
    ImmunityBio Raises $100M Including $75M Non-Dilutive Financing
    ImmunityBio Raises $100M Including $75M Non-Dilutive Financing

    31 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260331150858/en/ImmunityBio-Strengthens-Balance-Sheet-with-%24100-Million-of-Financing-Transactions-Including-%2475-Million-of-Non-Dilutive-Financing-to-Support-Global-Expansion-and-Advancement-of-Broader-Immunotherapy-Pipeline

    BUSINESSWIRE
    31 Mar 2026
    Share Share
    Robbins LLP Alerts Investors to ImmunityBio Action Lawsuit
    Robbins LLP Alerts Investors to ImmunityBio Action Lawsuit

    27 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-27/investor-notice-robbins-llp-informs-investors-of-the-immunitybio-inc-class-action-lawsuit

    PHARMIWEB
    27 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search